NCT02185690 - A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 7, 2017

Primary Completion Date

July 4, 2019

Study Completion Date

July 4, 2019

Conditions

Lungcancer

Interventions

DRUG

Binimetinib

"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."

DRUG

Pemetrexed

4-6 cycles given intravenously in combination with carboplatin as per standard therapy.

DRUG

Carboplatin

4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.

Trial Locations (4)

T6G1Z2

Cross Cancer Institute, Edmonton

L8V 5C2

Juravinski Cancer Centre, Hamilton

K1G 3Y9

The Ottawa Hospital Regional Cancer Centre, Ottawa

M5G2M9

Princess Margaret Cancer Centre, Toronto